Alpha-2-Macroglobulin
Alpha-2-macroglobulin (A2M)
Written by Aaron CuhaReviewed Sep 2026
Also known as: A2M, Alpha-2 macroglobulin, Pan-protease inhibitor
A broad-spectrum plasma protease inhibitor sold as a knee injection. The one randomised trial in 75 people found it no better than platelet-rich plasma or a steroid, and the authors concluded the extra cost is not justified.
Overview
Alpha-2-macroglobulin is a large plasma protein that traps and inactivates a wide range of proteases. Two separate interests converge on it. The longevity interest comes from the naked mole rat, a long-lived and cancer-resistant rodent: a 2015 comparative study found naked mole rat plasma carries roughly twice the A2M concentration of human plasma, 8.3 versus 4.4 mg/mL, with lower total plasma protein and higher antitryptic activity, and different predicted glycosylation. A 2019 human study found that A2M glycosylation features vary with age.
The orthopaedic interest is commercial and is the reason this entry carries community reports. A2M is concentrated from a patient's own blood and injected into arthritic joints, marketed on the rationale that it inhibits the cartilage-degrading enzymes involved in osteoarthritis.
That use has actually been tested, which is unusual for anything sold this way. A double-blinded randomised controlled trial at a single centre enrolled 75 people with symptomatic Kellgren-Lawrence grade 2 or 3 knee osteoarthritis, randomised to intra-articular A2M-rich concentrate, conventionally prepared platelet-rich plasma, or methylprednisolone, and followed them for 12 weeks; 68 of 75, that is 90.7 percent, completed. By 12 weeks the A2M group showed significant improvement on the visual analogue pain scale, WOMAC, KOOS and Tegner scores; the platelet-rich plasma group showed no significant improvement on any measure; and the steroid group improved on Lysholm only. The finding that decides the question is the between-group comparison: the changes from baseline to 12 weeks did not differ significantly between the three groups. The authors concluded that A2M shows comparable efficacy to platelet-rich plasma and corticosteroids, that the improvement was modest and inconsistent across measures, and that given its higher preparation cost it may not be a justifiable option for routine treatment of knee osteoarthritis.
No trial has tested A2M for ageing, longevity or any systemic indication.
Mechanism of action
Established human biochemistry: A2M is a tetrameric plasma glycoprotein that traps proteases of all four catalytic classes in a bait-and-trap conformational change, then clears the complex through the LRP1 receptor. The joint injection rationale is that it inhibits the matrix-degrading enzymes implicated in cartilage breakdown, and a 2024 minipig study reported that A2M reduced post-traumatic cartilage damage by inhibiting inflammatory pathways. The longevity rationale is comparative rather than mechanistic: the naked mole rat carries more A2M and more antitryptic activity than humans, and the authors suggest this may contribute to that species' cancer resistance and longevity. No mechanism linking A2M to human longevity has been demonstrated.
Human evidence
One randomised controlled trial exists and its between-group result is null. It was double-blinded, enrolled 75 people, and compared A2M knee injection against platelet-rich plasma and a corticosteroid; A2M improved on several measures within its own group, but the changes did not differ significantly between the three treatments. There is no human evidence for any systemic or ageing use.
- Randomised controlled trial (Bulletin of the Hospital for Joint Diseases 2024): 75 people with Kellgren-Lawrence grade 2 or 3 symptomatic knee osteoarthritis, single centre, double blinded, enrolled June 2018 to May 2019, randomised to A2M-rich concentrate, platelet-rich plasma or methylprednisolone, followed 12 weeks. 68 of 75 completed, 73 percent female, mean age 59, range 37 to 75. No significant baseline differences in age, sex or radiographic grade.
- Within-group results at 12 weeks: A2M improved significantly on visual analogue pain scale, WOMAC, KOOS and Tegner (p < 0.05). Platelet-rich plasma improved significantly on none of the patient-reported outcomes. Methylprednisolone improved on Lysholm only (p = 0.01).
- Between-group result, which is the one that answers the question: changes in patient-reported outcome scores from baseline to 12 weeks did not significantly differ between the three groups (p > 0.05).
- The authors' own conclusion: A2M shows comparable efficacy to platelet-rich plasma and corticosteroids, improvement was modest and inconsistent across measures, and given its increased preparation cost it may not be a justifiable option for routine treatment of knee osteoarthritis.
- Human observational work outside the joint: glycosylation features of A2M vary with age (Cell Biochemistry and Biophysics 2019).
- No human study has given A2M for ageing, longevity or any systemic indication, and none is registered.
What this does not tell you: Seventy-five people at one centre followed for 12 weeks cannot detect small differences between three active treatments, so a null between-group result here is compatible with a real but modest difference existing. Equally, within-group improvement in an injected joint over 12 weeks is exactly what placebo and regression to the mean produce, and the trial had no saline or sham arm, only three active comparators. Nothing in this trial addresses ageing. The naked mole rat work is comparative biochemistry between two species and supports no human claim at all.
Reading the research record
This page sits at an unusual intersection: a molecule with a longevity rationale drawn from a long-lived rodent, and a commercial orthopaedic product with an actual randomised trial behind it. The two literatures have nothing to do with each other, and the clinic marketing sometimes borrows the first to sell the second.
The randomised trial is the useful part and its result deserves to be read as the authors wrote it. A2M improved on four patient-reported measures within its own group, which is the number a clinic would quote. It did not beat platelet-rich plasma or a corticosteroid injection, and the study explicitly concludes that its higher preparation cost may not be justifiable. That is a head to head result and it gets reported here as evidence, including the part that does not flatter the product. There was no placebo arm, so the within-group improvement cannot be separated from the substantial placebo response known to follow any injection into a painful knee.
The naked mole rat comparison is interesting biology and is often presented as though it supported taking or injecting A2M. It does not. It reports that a different species has roughly twice the plasma concentration and higher antitryptic activity than humans, with different glycosylation. No experiment has raised A2M in a mammal to see whether lifespan or cancer incidence changes.
The evidence, charted
Fig. 1 · evidence composition
2of 4 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2015 to 2024, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2024
The Effectiveness of Alpha-2-Macroglobulin Injections for Osteoarthritis of the Knee
Double-blinded randomised controlled trial at a single centre, enrolling June 2018 to May 2019. 75 people with symptomatic Kellgren-Lawrence grade 2 or 3 knee osteoarthritis randomised to intra-articular A2M-rich concentrate, conventional platelet-rich plasma, or methylprednisolone, followed 12 weeks; 68 (90.7 percent) completed, 73 percent female, mean age 59. At 12 weeks the A2M group improved significantly on visual analogue scale, WOMAC, KOOS and Tegner; the platelet-rich plasma group improved on nothing; the steroid group improved on Lysholm only. Between-group changes did not differ significantly. The authors concluded A2M is not superior and, given higher preparation cost, may not be justifiable for routine treatment.
Bulletin of the Hospital for Joint Diseases - Animal2024
Alpha-2-Macroglobulin Attenuates Posttraumatic Osteoarthritis Cartilage Damage by Inhibiting Inflammatory Pathways With Modified Intra-articular Drilling in a Yucatan Minipig Model
Minipig. A2M reduced post-traumatic osteoarthritis cartilage damage by inhibiting inflammatory pathways, in a model combining joint injury with modified intra-articular drilling.
American Journal of Sports Medicine - In vitro2015
Analysis of Alpha-2 Macroglobulin from the Long-Lived and Cancer-Resistant Naked Mole-Rat and Human Plasma
Comparative analysis of naked mole rat and human plasma. Naked mole rat plasma carried A2M at 8.3 plus or minus 0.44 mg/mL versus 4.4 plus or minus 0.20 mg/mL in human plasma, with lower total plasma protein (38.7 versus 61.7 mg/mL), higher antitryptic activity, lower proteolytic activity, and a different predicted glycosylation giving a higher molecular weight. The authors suggest a possible contribution to that species' cancer resistance and longevity. This is comparative biochemistry, not an intervention.
PLoS One - Human2019
Age-Dependent Variation in Glycosylation Features of Alpha-2-Macroglobulin
Human observational. Glycosylation features of alpha-2-macroglobulin vary with age. A measurement of how the protein changes across the lifespan, not a test of any intervention.
Cell Biochemistry and Biophysics
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- A2M injections are offered in orthopaedic and regenerative medicine practice for knee and other joint osteoarthritis, prepared by concentrating the protein from a sample of the patient's own blood at the point of care. The marketed rationale is inhibition of cartilage-degrading enzymes.
- The trial that tested this use documents what the procedure involves and who receives it: people with radiographically confirmed Kellgren-Lawrence grade 2 or 3 knee osteoarthritis, mean age 59, mostly women, given a single intra-articular injection.
- Preparation cost is a documented practical issue rather than an anecdotal one: the trial authors name the increased cost of preparing A2M as part of their reason for concluding it may not be justifiable for routine use, given that it did not outperform cheaper alternatives.
- The comparators people are choosing between are the same ones the trial used: platelet-rich plasma and a corticosteroid injection. In that trial none of the three separated from the others over 12 weeks.
- Claims connecting A2M injections to longevity or to naked mole rat biology appear in marketing for this procedure. No study has tested A2M for ageing in any species, and the naked mole rat work is a comparison of plasma composition between two species.
Sources: The published randomised controlled trial in the Bulletin of the Hospital for Joint Diseases 2024, which is the source for the procedure description, the population treated, the comparators and the cost conclusion; the 2015 PLoS One naked mole rat comparative study, which is the source of the longevity rationale that appears in marketing. No clinic website, forum post or individual patient account is quoted or relied on here.
Frequently asked questions
Do A2M knee injections work?
In the one randomised controlled trial, 75 people with knee osteoarthritis received A2M, platelet-rich plasma or a corticosteroid. The A2M group improved significantly on four patient-reported measures over 12 weeks, but the changes did not differ significantly between the three groups. The authors concluded A2M is not superior and that its higher preparation cost may not be justifiable for routine treatment. There was no placebo arm.
Is A2M a longevity treatment?
No study has tested it for ageing in any species. The longevity rationale comes from a 2015 comparison showing naked mole rats, which are long-lived and cancer-resistant, carry about twice the plasma A2M of humans with higher antitryptic activity. That is a difference between two species, not evidence that raising A2M does anything in a person.
How does A2M compare to platelet-rich plasma?
In the head to head trial they did not differ. A2M improved significantly on visual analogue pain, WOMAC, KOOS and Tegner within its own group while platelet-rich plasma improved on none of them, but the between-group comparison, which is the one that answers the question, showed no significant difference between A2M, platelet-rich plasma and methylprednisolone at 12 weeks.
Is it safe?
The trial reported 68 of 75 participants completing 12 weeks and did not report a safety problem, but 75 people over 12 weeks is a small safety dataset. The injection is prepared from the patient's own blood, which avoids donor-related risks, and carries the ordinary risks of any intra-articular injection.